Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.94 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | CES1 | P23141 | 2/20 | 0.67 |
| ▸ | CES2 | O00748 | 1/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | PAM | P19021 | 2/20 | 0.56 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | FNTA | P49354 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylacetic Acid SCHEMBL27758886 | 0.97 | AKR1B1 (1.00) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL1459 | 0.97 | AKR1B1 (1.00) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL28242469 | 0.97 | AKR1B1 (1.00) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL1330777 | 0.97 | AKR1B1 (1.00) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL13618842 | 0.97 | AKR1B1 (1.00) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL9449909 | 0.97 | AKR1B1 (1.00) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL7214232 | 0.94 | AKR1B1 (0.94) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL6930087 | 0.94 | AKR1B1 (0.94) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL78313 | 0.94 | AKR1B1 (0.94) | AKR1B1ABCC4LMNAGAATSHR | |
| Phenylacetic Acid SCHEMBL11709776 | 0.94 | AKR1B1 (0.94) | AKR1B1ABCC4LMNAGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114438540-B | Application of photoelectrode loaded with Ag nano particles in photoelectrochemical synthesis of aromatic carboxylic acid | 中国科学院理化技术研究所 | 2023-04-28 | — | — | CN | claimed |
| CN-112384493-A | Process for the preparation of fused tricyclic gamma-amino acid derivatives and intermediates | 四川海思科制药有限公司 | 2021-02-19 | — | — | CN | claimed |
| CN-110872237-A | Application of novel methyl carbonate methylation catalyst in preparation of α -methylphenylacetic acid | 江苏瑞科医药科技有限公司 | 2020-03-10 | — | — | CN | claimed |
| CN-110872235-A | Application of novel methyl carbonate methylation catalyst in preparation of α -methylphenylacetic acid | 江苏瑞科医药科技有限公司 | 2020-03-10 | — | — | CN | claimed |
| CN-101172958-A | N,N*-2(2substituted phenyl) derivant of - 4-methoxy-1,3-benzol diamide and use of the same | UNIV TIANJIN TECHNOLOGY (CN) | 2008-05-07 | — | — | CN | claimed |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | ZGENE A/S (DK) | 2007-11-15 | — | — | US | claimed |
| US-7161008-B2 | Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them | Sanofi - Aventis Deutschland GmbH (DE) | 2007-01-09 | — | — | US | claimed |
| WO-2005079849-A2 | COMPOUNDS FOR ENHANCED CANCER THERAPY | ZGENE A/S (DK) | 2005-09-01 | — | — | WO | claimed |
| US-5883124-A | ADMINISTERING PHENYLACETIC ACID DERIVATIVE AND RETINOID TO TREAT TUMORS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-03-16 | — | — | US | claimed |
| US-5843994-A | Compositions and methods for treating and preventing pathologies including cancer | THE UNITED STATES OF AMERICA AS REPRESENETED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-12-01 | — | — | US | claimed |
| US-5712307-A | Methods of inducing the production of hemoglobin and treating pathologies associated with abnormal hemoglobin activity using phemylacetic acids and derivatives therof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-27 | — | — | US | claimed |
| US-5710178-A | ARYL- AND ARYLOXYALKANOIC ACIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-20 | — | — | US | claimed |
| US-5708025-A | BY INDUCING PRODUCTION OF FETAL HEMOGLOBINS BY ADMINISTERING SPECIFIED ARYL ACIDS, DERIVATIVES, SALTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-13 | — | — | US | claimed |
| US-5661179-A | ADMINISTERING; TREATS NEUROBLASTOMA, MYELODYSPLASIA, NON-SMALL CELL LUNG CANCER, PROSTATE CANCER, MELANOMA, BRAIN TUMOR, KAPOSI'S SARCOMA, LYMPHOMA, LEUKEMIA, BREAST AND LUNG CANCER, OSTEOSARCOMA AND FIBROSARCOMA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-26 | — | — | US | claimed |
| US-5654333-A | THERAPY FOR ANEMIA, CANCER, AIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-05 | — | — | US | claimed |
| US-5635533-A | ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | claimed |
| US-5635532-A | ADMINISTERING PHENYL OR NAPHTHYL ACETIC ACID DERIVATIVES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | claimed |
| US-5605930-A | ADMINISTERING PHENYLACETIC ACID AS AN INHIBITOR OF THE MEVALONATE PATHWAY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-02-25 | — | — | US | claimed |
| JP-56063940-A | — | — | None | — | — | JP | disclosed |
| US-4011336-A | ANTIPHLOGISTIC AGENTS | BASF AKTIENGESELLSCHAFT (DT) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | TYMP, BAD, NUDT1 | AKR1B1 712/4885ABCC4 1447/4885LMNA 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.